Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada.
Lawrence P RicherHuong LuuKaren J B MartinsKhanh VuAlexis GuigueKai On WongPhuong Uyen NguyenThilinie RajapakseTyler WilliamsonScott W KlarenbachPublished in: Headache (2023)
Of adults treated with botulinum toxin for chronic migraine, 75.2% had continued use, stable health resource and medication use, and costs over a 2 year period. In those that stopped/reduced use, the observed lower health resource and migraine medication use may indicate improved symptom control, but the resumption of guideline-recommended treatment intervals after reduced use was common.